{"id":"bgb-290","safety":{"commonSideEffects":[{"rate":"34%","effect":"Fatigue"},{"rate":"28%","effect":"Nausea"},{"rate":"25%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4112930","moleculeType":"Small molecule","molecularWeight":"298.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BGB-290 is a potent inhibitor of PARP1 and PARP2, enzymes involved in DNA repair and genomic stability.","oneSentence":"PARP inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:29.350Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Urothelial carcinoma"}]},"trialDetails":[{"nctId":"NCT04164199","phase":"PHASE3","title":"Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2019-12-19","conditions":"Advanced Malignancies","enrollment":404},{"nctId":"NCT03519230","phase":"PHASE3","title":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2018-05-14","conditions":"Ovarian Cancer","enrollment":224},{"nctId":"NCT03749187","phase":"PHASE1","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2019-04-03","conditions":"Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation","enrollment":78},{"nctId":"NCT05526924","phase":"PHASE1","title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":30},{"nctId":"NCT05038839","phase":"PHASE1","title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-09","conditions":"Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":44},{"nctId":"NCT03150862","phase":"PHASE1, PHASE2","title":"A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma","status":"COMPLETED","sponsor":"BeiGene USA, Inc.","startDate":"2017-07-24","conditions":"Brain and Central Nervous System Tumors","enrollment":116},{"nctId":"NCT03333915","phase":"PHASE1, PHASE2","title":"Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2016-12-21","conditions":"Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer","enrollment":128},{"nctId":"NCT03914742","phase":"PHASE1, PHASE2","title":"BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-02-16","conditions":"IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma","enrollment":67},{"nctId":"NCT02361723","phase":"PHASE1","title":"Phase 1a/1b BGB-290 for Advanced Solid Tumors.","status":"COMPLETED","sponsor":"BeiGene","startDate":"2014-07-03","conditions":"For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment","enrollment":101},{"nctId":"NCT03150810","phase":"PHASE1","title":"Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-06-28","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":139},{"nctId":"NCT03427814","phase":"PHASE2","title":"Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-07-03","conditions":"Advanced or Inoperable Gastric Cancer","enrollment":136},{"nctId":"NCT03575065","phase":"PHASE2","title":"Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-06-22","conditions":"HER2-negative Breast Cancer","enrollment":88},{"nctId":"NCT03994211","phase":"PHASE1","title":"Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-05-29","conditions":"Solid Tumor","enrollment":25},{"nctId":"NCT05573373","phase":"PHASE1","title":"Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2022-12-20","conditions":"Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04603365","phase":"PHASE2","title":"Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-10-18","conditions":"Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma","enrollment":""},{"nctId":"NCT05483543","phase":"PHASE2","title":"Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-20","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":44},{"nctId":"NCT05327621","phase":"PHASE2","title":"Pamiparib in mCRPC With HRD or BRCA1/2 Mutation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-05-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT02660034","phase":"PHASE1","title":"The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2016-02-02","conditions":"Solid Tumors","enrollment":229},{"nctId":"NCT03712930","phase":"PHASE2","title":"Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency","status":"TERMINATED","sponsor":"BeiGene","startDate":"2019-02-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)","enrollment":13},{"nctId":"NCT03933761","phase":"PHASE2","title":"Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy","status":"WITHDRAWN","sponsor":"Australia New Zealand Gynaecological Oncology Group","startDate":"2019-07-29","conditions":"Ovarian Cancer, Carcinosarcoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pamiparib"],"phase":"phase_2","status":"active","brandName":"BGB-290","genericName":"BGB-290","companyName":"BeiGene","companyId":"beigene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PARP inhibitor Used for Urothelial carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}